Cure8 research brief
Knowing a patient’s estimated infliximab clearance before starting rescue therapy for acute severe ulcerative colitis could help identify who may need higher or intensified induction dosing and who might be at greater risk of colectomy if standard dosing is used.
Adults with severe ulcerative colitis considering infliximab rescue therapy; clinicians managing ASUC; researchers and pharmacologists interested in TDM and personalised dosing of biologics.
This retrospective cohort from two Danish tertiary centres used a pharmacokinetic model (including sex, albumin, and anti-drug antibodies) to estimate infliximab clearance before treatment. Patients with ASUC had higher baseline clearance than outpatients, and a clearance threshold (≥0.42 L/day) was associated with subsequent use of intensified induction.
Among patients who were not intensified, those with high clearance had numerically higher 1-year colectomy rates; colectomy rates were similar regardless of clearance when intensified. The authors conclude that prospective validation of clearance-guided dosing is needed.
Retrospective cohort from two Danish tertiary centres reported in Frontline Gastroenterology; structured content depth is abstract and the authors recommend prospective validation. Do not interpret this as proof that clearance-guided dosing improves outcomes until prospective trials confirm benefit.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If you or a patient is about to start infliximab for ulcerative colitis, routine blood counts may help identify those unlikely to respond to induction therapy; a high negative predictive value suggests these markers...
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
